ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough

25th May 2018

10187

TAGS
alirocumab
PCSK9 inhibitor
Praluent
Sanofi Aventis

dawnpowell

RELATED ARTICLES MORE FROM AUTHOR

Alirocumab receives EC approval in established atherosclerotic cardiovascular disease

The European Commission authorise use of evolocumab to reduce risk of myocardial infarction in patients with established cardiovascular disease

ACC 2018: Alirocumab reduces cardiovascular events in high-risk patients

LEAVE A REPLY Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here

Δ

Most read in past 7 days

SCAI publishes expert consensus statement on sex-specific considerations in myocardial revascularisation

4th February 2022

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

10th March 2023

STS 2021: Study identifies significant gender disparities in CABG

30th January 2021

Features

Renal denervation “can reach new shores”

22nd February 2023

Cardiovascular-aortic community comes together at CX 2023

1st February 2023

The interventional cardiology trials to watch in 2023

30th January 2023

Profiles

Nieves Gonzalo

30th January 2023

Timothy D Henry

21st November 2022

Tom Nguyen

7th September 2022

Tweets by SpinalNewsInt

Write to us
Editorial: Will Date [email protected]
Advertising: Contact the Customer Relationship Manager [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Edit with Live CSS

Save
Write CSS OR LESS and hit save. CTRL + SPACE for auto-complete.